Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Indivior reports first-quarter growth, confirms plans to shift main listing
(Sharecast News) - Addiction treatment specialist Indivior reported double-digit net revenue growth for the first quarter on Thursday, with total net revenue rising 12% year-on-year to $284m, as it confirmed its intention to shift its primary listing to the United States. The FTSE 250 company said Sublocade net revenue jumped 36% to $179m in the three month period, compared to the same time last year.
It reaffirmed its full year guidance, expecting net sales and adjusted operating profit to accelerate throughout the year.
Additionally, the board confirmed its intention to seek shareholder approval in May for a primary listing in the US, aiming to better align with growth opportunities, attract more US investors, and enhance inclusion in US indices.
In terms of product highlights, Indivior said Sublocade continued its growth trajectory with increased net sales driven by increased penetration in the US health and justice systems.
US patient enrolments also showed significant growth, contributing to the positive performance.
Perseris net revenue meanwhile saw a 38% increase compared to the first quarter of 2023, reflecting increasing awareness across the US healthcare system.
Looking at financials, total net revenue increased 12% to $284m in the first quarter, with US net revenue growing 15% to $241m.
However, rest-of-world net revenue decreased 2% due to the timing of shipments and ongoing generic erosion of legacy products.
Gross margins remained strong at 84%, reflecting an improved product mix despite cost inflation.
Looking at its balance sheet and cash flow, Indivior reported a total of $356m in cash and investments at the end of the first quarter.
Cash used in operations primarily stemmed from litigation settlement payments, partially offset by income from operations.
The company said it was continuing to monitor principal risks, which remained consistent with those outlined in its 2023 annual report.
"Our first quarter results reflect continued double-digit top-line momentum led by Sublocade," said chief executive officer Mark Crossley.
"The underlying demand for this transformative treatment for moderate-to-severe opioid use disorder (OUD) remains strong and our strategy to expand prescribing in the justice system is delivering excellent results.
"Sublocade's reported growth was, however, adversely impacted by transitory items, including accelerating Medicaid patient disenrollments, a cyberattack on the largest US medical claims processor and abnormal trade destocking."
Crossley said the company fully expected those items to resolve as the year progressed and, combined with the benefits of recent commercial investments behind Sublocade, it anticipated an acceleration in its top- and bottom-line growth over the rest of 2024, particularly in the second half.
"We therefore reconfirm our 2024 guidance, including Sublocade net revenue of $820m to $880m and approximately 300 basis points of margin expansion at the mid-points of our guidance range.
"Lastly, after receiving strong indications of support from our shareholders, we are confirming our intention to seek shareholder approval in May 2024 to facilitate a primary listing in the US while maintaining a secondary listing in the UK."
At 0843 BST, shares in Indivior were down 6.87% at 1,410p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.